Data from Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non–Muscle-Invasive Bladder Cancer
Andrew Katims, Charlie White, Syed M. Alam, Mark Farha et autres
0 citations
Eugene J. Pietzak
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
296Publications signalées
3878Citations signalées
2Affiliations récentes
Les institutions déclarées
Les domaines associés
Bladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesCancer Immunotherapy and BiomarkersEpigenetics and DNA MethylationEsophageal Cancer Research and Treatment
Les publications récentes
Supplemental Figures from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
Brendan J. Guercio, Eugene J. Pietzak, Vignesh Ravichandran, Jie‐Fu Chen et autres
0 citations
Data from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
Brendan J. Guercio, Eugene J. Pietzak, Vignesh Ravichandran, Jie‐Fu Chen et autres
0 citations
Supplementary tables/figures1 from Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non–Muscle-Invasive Bladder Cancer
Andrew Katims, Charlie White, Syed M. Alam, Mark Farha et autres
0 citations
Supplementary Sequencing Data1 from Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non–Muscle-Invasive Bladder Cancer
Andrew Katims, Charlie White, Syed M. Alam, Mark Farha et autres
0 citations
Table S1 from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
Brendan J. Guercio, Eugene J. Pietzak, Vignesh Ravichandran, Jie‐Fu Chen et autres
0 citations
Supplementary Data from Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
Brendan J. Guercio, Eugene J. Pietzak, Vignesh Ravichandran, Jie‐Fu Chen et autres
0 citations
Chemoablation with oral erdafitinib in recurrent FGFR3 -altered non–muscle-invasive bladder cancer: A phase II window-of-opportunity trial.
Muhammad H. Alkazemi, Irina Ostrovnaya, Ao Zhang, Gal Wald et autres
us (code pays fourni par la source)
0 citations
Journal of Clinical Oncology
IP36-04 INTEGRATIVE CLINICAL AND MOLECULAR CHARACTERIZATION OF METASTASIS AND RESISTANCE TO ANTIBODY-DRUG CONJUGATES IN SARCOMATOID VARIANT BLADDER CANCER
Jiaqian Josie Luo, Sizhi P. Gao, Jacob E. Tallman, Fengshen Kuo et autres
0 citations
The Journal of Urology
PD25-09 TEMPORAL STABILITY OF ACTIONABLE GENOMIC AND PATHWAY ALTERATIONS IN NON-MUSCLE-INVASIVE BLADDER CANCER
Ali Ghasemzadeh, Vincent D’Andrea, Noah Frydenlund, Mark Farha et autres
0 citations
The Journal of Urology
Abstract LB191: Decoding metastasis and therapy resistance in sarcomatoid bladder cancer
Jiaqian Luo, Sizhi P. Gao, Jacob E. Tallman, Fengshen Kuo et autres
us (code pays fourni par la source)
0 citations
Cancer Research
Abstract 4036: Deciphering regulatory drivers of lineage plasticity and resistance to antibody-drug conjugates in urothelial bladder cancer
Jiaqian Luo, Sizhi Paul Gao, Jacob E. Tallman, Fengshen Kuo et autres
us (code pays fourni par la source)
0 citations
Cancer Research
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.